GuardianCon

Guardian Bio is a biotechnology company focused on developing next-generation dendritic cell therapies for the treatment of solid tumors. The company's proprietary platform generates "true" cDC1s (conventional Type 1 Dendritic Cells) from a patient's own hematopoietic stem cells, aiming to restore the immune system's ability to recognize and attack cancer. By revitalizing the antigen-presentation process, Guardian Bio's therapies are designed to stimulate a robust and diverse T-cell response against multiple tumor targets simultaneously. The company was founded by experts in immunology and regenerative medicine and is backed by Y Combinator.